The challenge of defining progression independent from relapse activity in MS

Emilio Portaccio, MD, University of Florence, Florence, Italy, discusses the complexities of defining progression independent of relapse activity (PIRA) in multiple sclerosis. He emphasizes the variability in clinical definitions, particularly regarding the time interval between disability progression, and suggests expanding this interval to avoid misidentifying PIRA. He also highlights the importance of having biomarkers indicative of PIRA and clinical measures beyond the Expanded Disability Status Scale (EDSS). This interview took place at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2024) in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.